There is a quote often attributed to Einstein: compound interest is the eighth wonder of the world. He who understands it, ...
Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
Imre Szenttornyay, CEO of Cielo IT LLC, empowers business owners to scale their operations profitably with AI-powered SmartSigns technology. When you manage a network of retail or franchise locations, ...
In software engineering as in all technical work, we find ourselves writing definitions of the concepts we need to work on. Often, such definitions leave much to be desired. In two earlier BLOG@CACM ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...
Gene sequencing company Illumina on Tuesday introduced a dataset that maps genetic changes to help accelerate drug discovery through artificial intelligence. December 8, 2025 Recursion Pharma's ...
Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results